UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders
Rhea-AI Summary
NorthStrive Biosciences (Nasdaq: ELAB) filed U.S. Patent Application No. 19/655,160 covering pharmaceutical formulations, dosing regimens, and method‑of‑use claims for EL-22, a myostatin‑engineered probiotic targeting muscle‑wasting conditions.
The claims span multiple indications including GLP‑1 receptor agonist–associated muscle loss, sarcopenia, muscle disuse atrophy, and certain neurological disorders, and the filing is positioned to expand the company’s layered intellectual property around EL-22.
AI-generated analysis. Not financial advice.
Positive
- Filed U.S. patent application 19/655,160 covering formulations and dosing regimens for EL-22
- Claims target multiple indications including GLP‑1–associated muscle loss, sarcopenia, disuse atrophy, and neurological disorders
- Expands EL-22 intellectual property across composition, formulation, and method‑of‑use claim categories
Negative
- Application filing does not confer issued patent rights; allowance is uncertain
- Announcement contains no clinical efficacy or human trial results for EL-22
News Market Reaction – ELAB
On the day this news was published, ELAB declined 0.39%, reflecting a mild negative market reaction. Argus tracked a trough of -12.8% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $44K from the company's valuation, bringing the market cap to $11.30M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ELAB gained 2.01% while close biotech peers were mixed: SPRC +26.89%, INDP +7.19%, QLGN +7.72%, REVB -1.29%, UBX -29.14%. With no peers in the momentum scanner and no same-day peer headlines, ELAB’s move appears stock-specific to the EL-22 patent update rather than a sector-wide rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Defense tech option | Positive | -5.5% | Exclusive option on GPS-denied autonomous drone navigation patent for defense uses. |
| Apr 21 | Supply agreement | Positive | -0.9% | SVM Machining long-term deal to supply mission-critical aerospace components. |
| Apr 17 | Equity facility | Neutral | -13.9% | Secured $40 million equity purchase facility to support M&A roll-up strategy. |
| Apr 13 | Biotech manufacturing | Positive | +6.0% | U.S. arrival of EL-32 WCB and manufacturing optimization for GLP-1 muscle preservation. |
| Apr 10 | Trade show outreach | Positive | -8.9% | Pacific Sun Packaging showcasing IT hardware packaging solutions at ITAD Europe 2026. |
Recent ELAB news has often seen negative price reactions even to seemingly constructive corporate developments, with the EL-32 muscle-preservation update as a notable positive outlier.
Over the last few weeks, PMGC/ELAB has reported multiple developments across defense, aerospace, packaging, and muscle-health probiotics. On April 13, a NorthStrive EL-32 manufacturing optimization update for GLP-1–related muscle preservation coincided with a +6.05% move. In contrast, structurally important financing news on April 17 tied to a $40 million equity facility saw shares fall 13.91%, and several aerospace contract wins in mid-April also met with negative reactions. Today’s EL-22 patent application builds on that muscle-health IP narrative but against a backdrop of prior dilution-focused filings and mixed trading responses.
Market Pulse Summary
This announcement extends NorthStrive’s EL-22 program with a new U.S. patent application covering formulations and dosing for GLP-1–associated muscle loss, sarcopenia, and other muscle-wasting conditions. It complements earlier EL-22 and EL-32 work highlighted in the April 13 EL-32 manufacturing update and the related 8-K filed on April 28. Investors may watch for progression from IP to clinical milestones, while also monitoring the impact of the recently disclosed $40,000,000 equity facility and other capital-structure actions on future dilution and funding flexibility.
Key Terms
glp-1 receptor agonists medical
myostatin medical
probiotic medical
muscle disuse atrophy medical
AI-generated analysis. Not financial advice.
- Filing seeks to extend EL-22 myostatin-engineered probiotic platform into pharmaceutical applications for muscle preservation in patients on GLP-1 receptor agonists and across multiple muscle-wasting indications
NEWPORT BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive” or the “Company”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC”), today announced the filing of a new U.S. patent application covering pharmaceutical formulations and dosing regimens of EL-22, the Company’s proprietary myostatin-engineered probiotic, for the treatment of muscle-wasting conditions, including muscle loss associated with GLP-1 receptor agonist therapy, sarcopenia, muscle disuse atrophy, and certain neurological disorders.
The application (U.S. Patent Application No. 19/655,160) is directed to pharmaceutical compositions, formulations, and dosing regimens of EL-22 for use in human patients, with claims spanning a broad range of muscle-wasting indications. The filing is part of NorthStrive’s strategy to build a layered intellectual property portfolio around EL-22 across composition, formulation, and method-of-use claims.
Loss of lean muscle mass is increasingly recognized as a clinically significant concern across multiple patient populations, including individuals receiving GLP-1 receptor agonist therapies for obesity and type 2 diabetes, older adults with sarcopenia, patients experiencing muscle disuse atrophy following injury or hospitalization, and individuals affected by certain neurological disorders. EL-22 is being developed to address muscle preservation across these settings, and the newly filed application is intended to expand NorthStrive’s patent coverage around the asset’s pharmaceutical use.
NorthStrive’s lead asset, EL-22, leverages a myostatin engineered probiotic approach designed to support muscle preservation and growth, including in patients undergoing weight loss treatments such as GLP-1 receptor agonists.
The newly filed application adds to NorthStrive’s growing intellectual property portfolio around EL-22 and supports the Company’s broader focus on muscle health therapeutics across pharmaceutical, metabolic, and adjacent healthcare markets.
Note: This press release is being re-released as an update to provide investors with an expanded and clearer description of the scope of the patent application, including the specific muscle-wasting indications addressed and the nature of the formulation, dosing, and method-of-use claims. There has been no change to the underlying patent filing, the application number, or the date of filing.
About NorthStrive Biosciences Inc.
NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focused on the development and acquisition of cutting-edge therapeutic technologies. The Company is advancing a pipeline of assets targeting muscle preservation, metabolic health, and related conditions.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across multiple industries. PMGC is focused on building long-term shareholder value through operational excellence and disciplined capital allocation. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although PMGC believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and PMGC cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of PMGC’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, PMGC undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
IR@pmgcholdings.com
